NO992226L - Nye forbindelser for anvendelse som neuro-protektive midler - Google Patents

Nye forbindelser for anvendelse som neuro-protektive midler

Info

Publication number
NO992226L
NO992226L NO992226A NO992226A NO992226L NO 992226 L NO992226 L NO 992226L NO 992226 A NO992226 A NO 992226A NO 992226 A NO992226 A NO 992226A NO 992226 L NO992226 L NO 992226L
Authority
NO
Norway
Prior art keywords
new compounds
neuroprotective agents
agents
neuroprotective
oxazolines
Prior art date
Application number
NO992226A
Other languages
English (en)
Other versions
NO313193B1 (no
NO992226D0 (no
Inventor
Lawrence J Heinz
Jill A Panetta
Michael L Phillips
John K Shadle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO992226D0 publication Critical patent/NO992226D0/no
Publication of NO992226L publication Critical patent/NO992226L/no
Publication of NO313193B1 publication Critical patent/NO313193B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19992226A 1996-10-07 1999-05-07 Nye forbindelser for anvendelse som neuro-protektive midler NO313193B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2756096P 1996-10-07 1996-10-07
PCT/US1997/017963 WO1998015274A1 (en) 1996-10-07 1997-10-06 Novel compounds useful as neuro-protective agents

Publications (3)

Publication Number Publication Date
NO992226D0 NO992226D0 (no) 1999-05-07
NO992226L true NO992226L (no) 1999-05-27
NO313193B1 NO313193B1 (no) 2002-08-26

Family

ID=21838447

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992226A NO313193B1 (no) 1996-10-07 1999-05-07 Nye forbindelser for anvendelse som neuro-protektive midler

Country Status (19)

Country Link
US (4) US6156748A (no)
EP (1) EP0971709B1 (no)
CN (1) CN1239889A (no)
AT (1) ATE240728T1 (no)
AU (1) AU721355B2 (no)
CA (1) CA2270661A1 (no)
CZ (1) CZ166399A3 (no)
DE (1) DE69722258T2 (no)
DK (1) DK0971709T3 (no)
EA (1) EA001713B1 (no)
ES (1) ES2199353T3 (no)
HU (1) HUP9904682A3 (no)
ID (1) ID21472A (no)
IL (1) IL129748A (no)
NO (1) NO313193B1 (no)
NZ (1) NZ335610A (no)
PT (1) PT971709E (no)
TR (1) TR199901559T2 (no)
WO (1) WO1998015274A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9034798A (en) * 1997-08-28 1999-03-16 Eli Lilly And Company Method for treating pain
US5952360A (en) * 1997-08-28 1999-09-14 Eli Lilly And Company Method for treating neuropathic pain
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6448396B2 (en) * 1997-10-06 2002-09-10 Eli Lilly And Company Compounds useful as neuro-protective agents
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
EP1218336A2 (en) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
RU2380362C2 (ru) * 1999-10-11 2010-01-27 Сосьете Де Консей Де Решерш З Производные пятичленных гетероциклов, способ их получения и их применение в качестве лекарственных средств
FR2812546B1 (fr) * 2000-08-01 2008-11-21 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
EP1358175A2 (en) * 2001-02-08 2003-11-05 Karo Bio Ab Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
US7179808B2 (en) 2002-07-03 2007-02-20 Janssen Pharmaceutica N.V. Substituted heteroaryl and heterocyclic compounds useful in treating inflammatory disorders
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
TW200505913A (en) 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
US7353897B2 (en) * 2003-07-23 2008-04-08 Fernandez Dennis S Telematic method and apparatus with integrated power source
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8637559B2 (en) 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
EP2614549B1 (de) 2010-09-06 2016-04-27 Aigys AG Betankbarer akku
WO2016179369A1 (en) 2015-05-07 2016-11-10 Impact Labs Llc Device for minimizing impact of collisions for a helmet
CN112826794B (zh) 2019-11-06 2022-02-11 上海交通大学医学院 一种靶向修复神经血管病变的纳米复合物及其制备与应用
WO2024040267A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
DE3425118A1 (de) * 1984-07-07 1986-01-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue redox-indikatoren
GB8531608D0 (en) * 1985-12-23 1986-02-05 Beecham Group Plc Treatment
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2009470A1 (en) * 1989-02-08 1990-08-08 Yu Momose Oxazole compounds and their use
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
DK0513379T3 (da) * 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
US5633271A (en) * 1992-05-26 1997-05-27 E. I. Du Pont De Nemours And Company Arthropodicidal oxazolines and thiazolines
DE4304197A1 (de) * 1993-02-12 1994-08-18 Bayer Ag Substituierte Oxazole
US5428048A (en) * 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US5952360A (en) * 1997-08-28 1999-09-14 Eli Lilly And Company Method for treating neuropathic pain
AU9034798A (en) * 1997-08-28 1999-03-16 Eli Lilly And Company Method for treating pain
US6448396B2 (en) * 1997-10-06 2002-09-10 Eli Lilly And Company Compounds useful as neuro-protective agents

Also Published As

Publication number Publication date
HUP9904682A2 (hu) 2000-05-28
ATE240728T1 (de) 2003-06-15
EP0971709A1 (en) 2000-01-19
AU721355B2 (en) 2000-06-29
EA001713B1 (ru) 2001-08-27
EA199900362A1 (ru) 2000-02-28
DK0971709T3 (da) 2003-09-22
CN1239889A (zh) 1999-12-29
EP0971709B1 (en) 2003-05-21
CZ166399A3 (cs) 1999-11-17
ID21472A (id) 1999-06-17
EP0971709A4 (en) 2001-04-11
DE69722258T2 (de) 2004-03-18
PT971709E (pt) 2003-09-30
DE69722258D1 (de) 2003-06-26
US6166216A (en) 2000-12-26
US20020065274A1 (en) 2002-05-30
US6156748A (en) 2000-12-05
TR199901559T2 (xx) 1999-09-21
NO313193B1 (no) 2002-08-26
US6423709B1 (en) 2002-07-23
HUP9904682A3 (en) 2001-09-28
IL129748A (en) 2003-11-23
NZ335610A (en) 2000-10-27
ES2199353T3 (es) 2004-02-16
AU4745997A (en) 1998-05-05
IL129748A0 (en) 2000-02-29
CA2270661A1 (en) 1998-04-16
US6380213B1 (en) 2002-04-30
WO1998015274A1 (en) 1998-04-16
NO992226D0 (no) 1999-05-07

Similar Documents

Publication Publication Date Title
NO992226L (no) Nye forbindelser for anvendelse som neuro-protektive midler
TR200103612T2 (tr) Tiazol ve oksazol türevleri ve farmasötik kullanımları
DK1349843T3 (da) Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
NO924696L (no) Fremgangsmaate for fremstilling av oksazolidinon- og tiazolidinon-derivater
NO20054195D0 (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
NO20022467L (no) Substituerte oksazol- og tiazol-derivater som HPPAR-alfa- aktivatorer
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
BR0013493B1 (pt) derivado de oxazol, composição farmacêutica, composto, e, uso de um derivado de oxazol ou um sal do mesmo
BR9509673A (pt) Compostos e uso dos mesmos
DK0699192T3 (da) Substituerede oxazolylforbindelser til behandling af inflammation
NO995846D0 (no) Oksazolidinon-antibakterielle midler med en tiokarbonylfunksjonalitet
DE60024414D1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
SE9702305D0 (sv) New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
NO20062629L (no) Oksazolderivater av tetrackliner
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
TR200100352T2 (tr) Nöro-koruyucu maddeler olarak yararlı yeni bileşikler
DE60223805D1 (de) Oxazol/thiazol-derivate als aktivatoren des hppar-alpha-rezeptors
ATE412413T1 (de) Oxazolidin tablettenformulierung
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
NO954892D0 (no) Heterosyklisk kjemi
AR048948A1 (es) Una composicion farmaceutica antimicobacteriana
DK1032386T3 (da) Anvendelse af oxazolidinonderivater til behandling af arthritis
NO20032582L (no) 1,2,4-oksadiazolderivater som HPPAR alfa agonister
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
ATE329913T1 (de) Oxazole als mglur1 verstärker

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees